MailMyPrescriptions is a licensed and accredited US Pharmacy with the following Certifications:
Powered by GeniusRx
How does an FSA work?
Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Cyproheptadine hydrochloride shares the actions and uses of the other antihistamines. In addition, cyproheptadine is used for the treatment of cold urticaria, and some clinicians consider it the drug of choice for the treatment of this condition.
Cyproheptadine has been effective in some patients for the treatment of Cushing's syndrome secondary to pituitary disorders. Clinical remissions and normalization of cortisol indexes (i.e., cortisol secretion rate, plasma cortisol concentration, urinary free cortisol excretion) reportedly occur in up to 60% of patients, generally within 1-3 months after beginning treatment. Although almost all of these patients relapse after discontinuance of cyproheptadine, prolonged remission (e.g., for at least 2.5-3 years) has occurred in a few patients following discontinuance of the drug. If relapse occurs, additional courses of therapy usually produce further responses. The role of cyproheptadine in the treatment of Cushing's syndrome secondary to pituitary disorders remains to be clearly established; in most patients, other therapy (e.g., surgery, radiation therapy) is preferred.
Cyproheptadine has been effective for the management of inhibited male or female orgasm (anorgasmy) induced by tricyclic antidepressants, monoamine oxidase inhibitors, fluoxetine, or antipsychotic agents. Ability to achieve orgasm was restored when cyproheptadine was administered 1-2 hours before anticipated sexual activity (e.g., 4-12 mg) or daily (e.g., 1-16 mg daily). Although not clearly established, the efficacy of cyproheptadine in these patients may be related to its serotonin antagonist or anticholinergic activity. However, the potential for drug interaction (possibly resulting in anticholinergic toxicity or additive CNS depression) in patients receiving any of these drugs concomitantly with cyproheptadine should be kept in mind. In a limited number of patients receiving cyproheptadine for fluoxetine-induced ejaculatory dysfunction, cyproheptadine reversed the antidepressant effects of fluoxetine. The mechanism of this drug interaction is not known, but it has been postulated that cyproheptadine, a serotonin antagonist, may inhibit the serotonergic effects of fluoxetine.
Although there are few indications for clinical use, cyproheptadine has been shown to stimulate appetite and weight gain in children and adults. There is evidence that cyproheptadine may be of some value in the management of anorexia nervosa, but the drug may be more effective in patients with anorexia nervosa who do not undertake periodic episodes of binge eating (nonbulimic) than those who do (bulimic).
Cyproheptadine reportedly has been effective in some patients for the management of vascular headaches (e.g., migraine). While clinical efficacy of cyproheptadine in the prophylaxis of migraine headache has not been established in randomized controlled studies, some experts consider the drug to be effective based on consensus and clinical experience. For further information on management and classification of migraine headache,
Cyproheptadine reportedly has been effective in some patients for the management of Nelson's syndrome, virilizing congenital adrenal hyperplasia in adult females, galactorrhea-amenorrhea syndrome, and carcinoid syndrome.
Cyproheptadine has been used as an adjunct to somatropin (human growth hormone) therapy in a limited number of children with somatotropin (endogenous growth hormone) deficiency. Combined therapy with the drugs was more effective in promoting weight gain and linear growth in these children than somatropin alone, but additional study is necessary.
Dosage and Administration
Cyproheptadine hydrochloride is administered orally.
Dosage of cyproheptadine hydrochloride should be individualized according to the patient's response and tolerance. For geriatric patients, the manufacturer suggests that cyproheptadine hydrochloride dosage be initiated in the lower end of the usual range.
For the treatment of allergic conditions, the usual initial adult dosage of cyproheptadine hydrochloride is 4 mg 3 times daily. Dosage may be increased, if necessary, but total dosage in adults should not exceed 0.5 mg/kg daily. The usual dosage range in adults is 4-20 mg daily; most adults require 12-16 mg daily. Some patients may require a dosage as high as 32 mg daily.
The usual dosage of cyproheptadine hydrochloride for children 2-6 years of age is 2 mg 2 or 3 times daily; dosage should not exceed 12 mg daily.(See Cautions: Pediatric Precautions.) For children 7-14 years of age, the usual dosage is 4 mg 2 or 3 times daily; dosage should not exceed 16 mg daily. For adolescents 15 years of age and older, the initial dosage is 4 mg 3 times daily; dosage should not exceed 0.5 mg/kg daily. The usual dosage range in adolescents 15 years of age and older is 4-20 mg daily; most patients require 12-16 mg daily. Alternatively, children 2 years of age and older may receive 0.25 mg/kg or 8 mg/m daily in divided doses.
For the treatment of Cushing's syndrome secondary to pituitary disorders, the usual initial adult dosage of cyproheptadine hydrochloride is 8 mg daily in divided doses; dosage is gradually increased to up to 24 mg daily in divided doses.
For the management of anorexia nervosa in adults and children 13 years of age and older, cyproheptadine hydrochloride has been administered at an initial dosage of 2 mg 4 times daily and then gradually increased over a 3-week period to up to 8 mg 4 times daily.
Cyproheptadine hydrochloride shares the toxic potentials of other antihistamines, and the usual precautions of antihistamine therapy should be observed.
Safety and efficacy of cyproheptadine in children younger than 2 years of age have not been established and, like other antihistamines, the drug should not be used in premature or full-term neonates. and
Clinical studies of cyproheptadine did not include sufficient numbers of patients 65 years of age and older to determine whether geriatric patients respond differently than younger patients. While clinical experience generally has not revealed age-related differences in response to the drug, care should be taken in dosage selection of cyproheptadine. Because of the greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy in geriatric patients, the manufacturer suggests that patients in this age group receive initial dosages of the drug in the lower end of the usual range.
Mutagenicity and Carcinogenicity
Long-term studies to determine the carcinogenic potential of cyproheptadine have not been performed to date. No evidence of cyproheptadine-induced mutagenic activity was seen in vitro in the Ames microbial mutagen test, although concentrations of the drug greater than 0.5 mg/plate inhibited bacterial growth. Chromosomal abnormalities also were not evident in in vitro mammalian (human lymphocytes or fibroblasts) test systems, but high concentrations were cytotoxic.
Pregnancy, Fertility, and Lactation
Reproduction studies in rabbits, mice, and rats using oral or subcutaneous cyproheptadine hydrochloride dosages up to 32 times the maximum recommended human oral dosage have not revealed evidence of harm to the fetus. Although the drug has been fetotoxic in rats when administered intraperitoneally at dosages 4 times the maximum recommended human oral dosage, experience in a limited number of women who received cyproheptadine orally during the first, second, and/or third trimesters of pregnancy did not reveal evidence of an increased risk of fetal abnormalities, nor were teratogenic effects observed in neonates born to these women. No evidence of adverse fetal effect was evident in an infant born to a woman who had received 12 mg of cyproheptadine hydrochloride daily throughout pregnancy for the treatment of Cushing's syndrome; the infant developed normally until 4 months of age when he developed gastroenteritis and died. Nevertheless, because the reported experience to date in humans cannot exclude the possibility of adverse fetal effects of the drug, cyproheptadine should be used during pregnancy only when clearly needed.
Reproduction studies in animals using cyproheptadine hydrochloride dosages up to 32 times the maximum recommended human oral dosage have not revealed evidence of impaired fertility. Successful pregnancy has occurred in several women who received cyproheptadine for the treatment of Cushing's syndrome; the women were amenorrheic prior to therapy with the drug.
It is not known whether cyproheptadine hydrochloride is distributed into milk. Because of the potential for serious adverse reactions to cyproheptadine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
Cyproheptadine hydrochloride appears to be well absorbed following oral administration. Following a single oral dose of radiolabeled drug in fasting healthy adults in one study, peak plasma concentrations of radioactivity occurred 6-9 hours after administration; the radioactivity appeared to represent cyproheptadine metabolites.
Distribution of cyproheptadine into human body tissues and fluids has not been characterized. It is not known if the drug is distributed into milk.
The metabolic and excretory fate of cyproheptadine has not been fully elucidated. The drug appears to be almost completely metabolized, principally to the quaternary ammonium glucuronide conjugate. The drug also undergoes aromatic ring hydroxylation, N-demethylation, and heterocyclic ring oxidation. Most cyproheptadine metabolites appear to be conjugated with glucuronic acid or sulfate.
Cyproheptadine metabolites are excreted principally in urine, almost completely as conjugates. The drug does not appear to be excreted unchanged in urine. Cyproheptadine and some metabolites are excreted in feces following oral administration; whether such excretion occurs via biliary elimination remains to be established. Following a single oral dose of cyproheptadine hydrochloride in healthy adults, about 30% of the dose is excreted as metabolites in urine within 24 hours, about 50% within 48 hours, and about 65-75% within 6 days; the remainder of the dose is excreted in feces. The principal urinary metabolite is the quaternary ammonium glucuronide conjugate; during chronic administration of 12-20 mg of cyproheptadine daily in patients with anorexia nervosa who had normal renal and hepatic function, an average of 24% of the daily dose was excreted in urine as this metabolite. Elimination of cyproheptadine is reduced in renal insufficiency.